Pharmaceuticals

Santen: A clear view of drug repurposing and a loss of sleep for those relying on Neurim

The CJEU has dealt a massive blow to the drug repurposing sector with its decision in Santen, stripping companies of their right to Supplementary Protection Certificates (SPCs), and overturning one of the most influential SPC cases of all time: Neurim. SPCs provide up to five years of market exclusivity for...

Read more

SPCs: What it means to be protected by a patent

Further guidance has come from the CJEU on the disclosure requirements in a patent of a medicinal drug for it to be awarded a Supplementary Protection Certificate (SPC), and the associated market exclusivity, in Europe. Unlike the case for infringement, it is not enough for the medicinal drug, or “product”,...

Read more

Wisdom of the crowd: how to make sure IP doesn’t derail your crowdfunding efforts

Startups raising hundreds of thousands – even millions – of pounds via Kickstarter may be rarer than it once was, but crowdfunding remains a popular method of fundraising. There are a myriad of options, whether you go down the equity crowdfunding route offered by the likes of Seedrs, CrowdCube, and...

Read more

Bittersweet News for Employee Compensation in the Pharmaceutical Sector

The UK Supreme Court’s decision in Shanks v Unilever has provided some guidance on the circumstances that may lead to an inventor being entitled to a financial reward from their employer under UK law. The court awarded Professor Shanks a £2 million pay-out after finding that a biosensor for measuring glucose...

Read more

Big Tech Companies on the Healthcare Market

When you hear about the likes of “Apple”, “Amazon”, “Facebook”, “Google” and Microsoft”, healthcare is not typically the first thing that springs to mind. However, in recent years these tech giants have been emerging in the healthcare sector. What triggered this diversity in their market strategy? How might this affect...

Read more